Former FDA cancer chief Pazdur says the agency should restructurenews2026-07-22T18:46:02+00:00July 22nd, 2026|Endpoints News|
Novartis CEO says latest China deals are just following the sciencenews2026-07-21T15:41:54+00:00July 21st, 2026|Endpoints News|
Braveheart files for IPO to fund Phase 3 of Hengrui’s Cytokinetics rivalnews2026-07-15T12:52:00+00:00July 15th, 2026|Endpoints News|
Insilico, Bora Pharma reveal plans for AI-driven manufacturing companynews2026-07-15T12:30:44+00:00July 15th, 2026|Endpoints News|
AstraZeneca to take rights to Dizal’s lung cancer pill Zegfrovynews2026-07-14T10:38:24+00:00July 14th, 2026|Endpoints News|
In latest deal, Innovent seeds Spero’s future beyond GSK-owned antibioticnews2026-07-14T10:00:48+00:00July 14th, 2026|Endpoints News|
Former Akero team announces new I&I company, Avere, with China drugnews2026-07-14T10:00:05+00:00July 14th, 2026|Endpoints News|
FDA rejects Hengrui-Elevar liver cancer drug combo for third timenews2026-07-10T17:42:38+00:00July 10th, 2026|Endpoints News|
US biotechs turn secretive as they fear competition from rising Chinese industrynews2026-07-10T16:00:15+00:00July 10th, 2026|Endpoints News|
Sino Biopharm hooks AstraZeneca, GSK for separate respiratory partnershipsnews2026-07-08T10:56:37+00:00July 8th, 2026|Endpoints News|
